Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals
暂无分享,去创建一个
X. Zu | L. Qi | Longfei Liu | Long Wang | Yao He | Zhenzhen Cao | Z. Ou | Zhi Wang | Yuan Li | Longxiang Wu | D. A. Dube | Zhenyu Ou
[1] Yue Xu,et al. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells , 2017, Oncotarget.
[2] H. Xie,et al. Aberrant Transforming Growth Factor‐β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia , 2016, Stem cells translational medicine.
[3] M. Carini,et al. Benign Prostatic Hyperplasia, Metabolic Syndrome and Non‐Alcoholic Fatty Liver Disease: Is Metaflammation the Link? , 2016, The Prostate.
[4] C. Roehrborn,et al. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. , 2016, The Journal of urology.
[5] J. Ryu,et al. Proliferation of Prostate Stromal Cell Induced by Benign Prostatic Hyperplasia Epithelial Cell Stimulated With Trichomonas vaginalis via Crosstalk With Mast Cell , 2016, The Prostate.
[6] X. Chen,et al. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR , 2016, Oncotarget.
[7] X. Zu,et al. LPS/TLR4 Signaling Enhances TGF-β Response Through Downregulating BAMBI During Prostatic Hyperplasia , 2016, Scientific Reports.
[8] Melissa M. Norström,et al. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes , 2016, Oncotarget.
[9] S. Yeh,et al. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals , 2015, Oncotarget.
[10] R. Sagi-Eisenberg,et al. Down-regulation of the A3 adenosine receptor in human mast cells upregulates mediators of angiogenesis and remodeling. , 2015, Molecular immunology.
[11] Qiang Yu,et al. Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner. , 2015, Biochemical and biophysical research communications.
[12] J. Marshall,et al. Mast cells as targets for immunotherapy of solid tumors. , 2015, Molecular immunology.
[13] Hua Yu,et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.
[14] M. Raica,et al. Mast cell phenotype in benign and malignant tumors of the prostate. , 2014, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[15] A. Tewari,et al. Inflammation and prostate cancer: the role of interleukin 6 (IL‐6) , 2014, BJU international.
[16] S. Xie,et al. Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium. , 2014, International journal of clinical and experimental pathology.
[17] R. Hwang,et al. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. , 2013, Cancer research.
[18] H. Jung,et al. Is Increased Prostatic Urethral Angle Related to Lower Urinary Tract Symptoms in Males with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms? , 2012, Korean journal of urology.
[19] Xiaohai Wang,et al. Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia (BPH) , 2012, The Journal of Biological Chemistry.
[20] I. Alafuzoff,et al. Mast Cell Accumulation in Glioblastoma with a Potential Role for Stem Cell Factor and Chemokine CXCL12 , 2011, PloS one.
[21] Robert L. Sutherland,et al. Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.
[22] A. Kozubík,et al. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. , 2010, Cellular signalling.
[23] G. Ling,et al. Mast Cell Infiltration Is Involved in Renal Interstitial Fibrosis in a Rat Model of Protein-Overload Nephropathy , 2010, Kidney and Blood Pressure Research.
[24] M. Truss,et al. Quantitative Study of Mast Cells in Experimentally Induced Benign Prostatic Hyperplasia , 2010, Urologia Internationalis.
[25] S. Terry,et al. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis , 2009, The Prostate.
[26] G. Kramer,et al. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? , 2007, European urology.
[27] E. Bergstralh,et al. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia , 2006, The Prostate.
[28] A. Aydın,et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. , 2006, Clinical biochemistry.
[29] Lieve Moons,et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.
[30] L. Hültner,et al. Mast cells and inflammation. , 2002, Archivum immunologiae et therapiae experimentalis.
[31] T. Hirano,et al. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.
[32] G. Nilsson,et al. Phenotypic Characterization of the Human Mast‐Cell Line HMC‐1 , 1994, Scandinavian journal of immunology.